Regeneron’s Murphy sells $3.2 million in stock under plan (NASDAQ: REGN)

What happened

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) said Co-Chief Scientific Officer Andrew J. Murphy sold 4,147 shares on 10/14/2026. The shares sold for $753.76 to $781.47 each and brought in about $3.20 million, according to the Form 4. The filing says the trades were made under a Rule 10b5-1 trading plan.

The same filing shows Murphy acquired 17,000 shares of common stock on 10/13/2026 at $381.92 through a non-qualified stock option. After these transactions, Murphy held 47,833 shares. The form also lists 4,414 shares held indirectly by a 401(k) Plan. The plan was adopted on May 7, 2026. The form was filed on 10/15/2026.

Key numbers

Metric	Latest	Change	Source
Shares sold	4,147 shares		SEC Form 4
Sale price range	from $753.76 to $781.47 per share		SEC Form 4
Sale value	about $3.20 million		SEC Form 4
Shares held after	47,833 shares		SEC Form 4
Option exercise	17,000 shares		SEC Form 4

Read more: Regeneron Pharmaceuticals (REGN) stock analysis and investment case

Why it matters

OptimistFi's case is that Regeneron converts a concentrated portfolio of approved biologics into durable free cash flow that funds R&D, buybacks and pipeline investment. This filing is mixed for that view because Murphy's 4,147-share sale was about 8.0% of the 51,980 shares held before the sale sequence. The option exercise added 17,000 shares at $381.92 before the sales.

The main offset is in the filing itself. The trades were made under a Rule 10b5-1 trading plan. Murphy still held 47,833 shares afterward, and the filing ties the plan to a May 7, 2026 adoption date. The reported sale prices and the 17,000-share option exercise show how the stake moved from 51,980 shares to 47,833 shares. That is the current baseline until the next quarterly report.

Browse: stock research on every company OptimistFi covers

What's next

Regeneron Pharmaceuticals, Inc.'s next quarterly report is the next scheduled test for the investment case. A stronger report would support the thesis on free cash flow, buybacks and pipeline investment. This Form 4 is a snapshot of one officer's trades and one option exercise, filed on 10/15/2026. The filing date is 10/15/2026, the same day Murphy signed the form. The reported sale prices and the exercise price give a clear benchmark for the stake in this filing.

More from OptimistFi